research use only
Cat.No.S4176
|
In vitro |
Water : 24 mg/mL
DMSO
: 2 mg/mL
(16.5 mM)
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 121.14 | Formula | C4H11NO3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 77-86-1 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Tromethamine | Smiles | C(C(CO)(CO)N)O | ||
| Targets/IC50/Ki |
proton acceptor
|
|---|---|
| In vitro |
Trometamol is a proton acceptor that generates NH3 +/HCO3 - without generating CO2, and the protonated R-NH3 + is eliminated by the kidneys. This compound is the buffer of choice in the situation where CO2 elimination is impaired (in which case NaHCO3 cannot correct acidemia), and to avoid a Na+ load. Even during short intervals of apneic oxygenation when CO2 elimination is curtailed, this chemical, but not bicarbonate, will maintain a normal arterial pH. It also acts as an osmotic diuretic, increasing urine flow, urinary pH, and excretion of fixed acids, carbon dioxide and electrolytes. A significant fraction of this compound is not ionized and therefore is capable of reaching equilibrium in total body water. This portion may penetrate cells and may neutralize acidic ions of the intracellular fluid. |
| In vivo |
The drug is rapidly eliminated by the kidney; 75% or more appears in the urine after eight hours. Urinary excretion continues over a period of three days. The maximum daily dose is 15 mmol/kg for an adult. In large doses, this compound may induce respiratory depression and hypoglycemia. |
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02086097 | Completed | Irreversible Pulpitis |
Daniel Chavarría Bolaños|Universidad Autonoma de San Luis Potosí |
August 2013 | Phase 4 |
| NCT01365611 | Completed | Healthy Subjects |
Egalet Ltd |
February 2007 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.